Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 1.2% – What’s Next?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)’s share price dropped 1.2% on Monday. The stock traded as low as $2.52 and last traded at $2.53. 8,568 shares were traded during mid-day trading, a decline of 37% from the average session volume of 13,526 shares. The stock had previously closed at $2.56.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Kiora Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Kiora Pharmaceuticals Stock Up 1.1%

The stock has a market capitalization of $11.18 million, a P/E ratio of -1.01 and a beta of -0.22. The company has a fifty day moving average price of $2.60 and a 200-day moving average price of $2.51.

Kiora Pharmaceuticals (NASDAQ:KPRX) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.13.

Institutional Investors Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new stake in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC bought a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 167,941 shares of the company’s stock, valued at approximately $442,000. ADAR1 Capital Management LLC owned about 3.80% of Kiora Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies for serious ophthalmic diseases. The company’s research programs are designed to address conditions affecting the retina and other parts of the eye, including diseases for which treatment options remain limited.

Kiora’s lead candidate, KIO-301, is an investigational small-molecule therapy being developed to restore or improve visual function in patients with inherited retinal diseases, including retinitis pigmentosa.